Rituximab for childhood nephrotic syndrome: a follow-up study
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows children with nephrotic syndrome (a kidney condition causing swelling) who are being treated for the first time with rituximab. It aims to see how well the medication works long-term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 18 years old.
- Your child must have a type of nephrotic syndrome that comes back often, needs steroids to stay controlled, or doesn't respond to steroids.
- This must be the first time your child receives rituximab for their nephrotic syndrome.
- Your child's nephrotic syndrome should not be caused by other conditions like lupus, IgA nephropathy, or hepatitis.
- Your child's kidney function must be good (estimated filtration rate at least 60 mL/min/1.73m²).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
This trial tests an experimental medicine called zuberitamab in children who have just had their first episode of nephrotic syndrome and responded well to steroid treatment. The medicine targets certain immune cells to help keep the disease from coming back.
This trial tests rituximab, a medicine that affects the immune system, in children who have their first episode of steroid-sensitive nephrotic syndrome and are in remission at enrollment. It aims to see whether rituximab helps prevent relapse and improves kidney outcomes with fewer steroid needs.
This study tests a combination of two medicines, rituximab and low-dose mycophenolate, to treat a type of kidney inflammation called proliferative lupus nephritis in children. It aims to see if the combination works well and is safe for kids with active lupus affecting the kidneys.
This trial tests whether rituximab works as well as mycophenolate in children whose nephrotic syndrome (kidney condition) comes back when steroid medicines are reduced. It aims to find the safest and most effective option during a relapse.
Hear when a new Nephrotic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.